Kwang Dong Pharmaceutical (009290) Fundamentals 2026 — P/E 11.4x, Revenue Analysis | SniperIQ
Kwang Dong Pharmaceutical (009290) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩235.4B, trading at ₩5850.00 on the KSC. This SniperIQ fundamentals page covers Kwang Dong Pharmaceutical's valuation (P/E 11.4x, P/B 0.4x), profitability (net margin 1.3%), revenue (₩1.66T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Kwang Dong Pharmaceutical's market cap?
Kwang Dong Pharmaceutical (009290) has a market capitalization of approximately ₩235.4B, trading at ₩5850.00 on the KSC. Market cap moves with the live share price.
What is Kwang Dong Pharmaceutical's P/E ratio?
Kwang Dong Pharmaceutical's trailing twelve-month P/E ratio is 11.4x, with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Kwang Dong Pharmaceutical?
Kwang Dong Pharmaceutical runs a net profit margin of 1.3%, a gross margin of 17.6%, and an operating margin of 2.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Kwang Dong Pharmaceutical generate?
Kwang Dong Pharmaceutical reported revenue of ₩1.66T for fiscal year 2025, with net income of ₩21.0B and earnings per share (EPS) of 521. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Kwang Dong Pharmaceutical pay a dividend?
Kwang Dong Pharmaceutical offers a trailing dividend yield of about 1.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Kwang Dong Pharmaceutical financially healthy?
Kwang Dong Pharmaceutical carries a debt-to-equity ratio of 0.47x and a current ratio of 1.30x, with a market beta of 0.36. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Kwang Dong Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Kwang Dong Pharmaceutical (009290) the key facts are: market cap ₩235.4B, P/E 11.4x, revenue ₩1.66T, 52-week range 5150-12800. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Kwang Dong Pharmaceutical's full fundamentals live
Get Kwang Dong Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.